# Cardiac Safety Evaluation of P03277

> **NCT03657264** · PHASE1 · COMPLETED · sponsor: **Guerbet** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** P03277 0.1 mmol/kg
- **DRUG:** Moxifloxacin 400mg
- **DRUG:** NaCl 0.9%
- **DRUG:** P03277 0.3 mmol/kg

## Key facts

- **NCT ID:** NCT03657264
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-21
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-06-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657264, "Cardiac Safety Evaluation of P03277". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03657264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*